A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data
Authors:
- 1 August 2005
- journal article
- clinical trial
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 3 (3) , 137-145
Abstract
Background: Rapid genetic screening for cytochrome P450 (CYP) 2C9 variants may play a role in improving the efficacy and safety of warfarin in individuals with CYP2C9 variants. The feasibility of prospective CYP2C9 model-based warfarin dosing has not yet been assessed.Keywords
This publication has 14 references indexed in Scilit:
- Relative impact of covariates in prescribing warfarin according to CYP2C9 genotypePharmacogenetics, 2004
- Use of pharmacogenetics to guide warfarin therapyDrugs of Today, 2004
- Managed care in the genomics era: assessing the cost effectiveness of genetic tests.2003
- American Heart Association/American College of Cardiology Foundation Guide to Warfarin TherapyCirculation, 2003
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearanceClinical Pharmacology & Therapeutics, 2002
- CYP2C9 allelic variants: ethnic distribution and functional significanceAdvanced Drug Delivery Reviews, 2002
- Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin TherapyJAMA, 2002
- Interindividual variability in sensitivity to warfarin-Nature or nurture?Clinical Pharmacology & Therapeutics, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996